Stockscreener 앱 받기
6.51
0.31%
-0.02
전일 마감가:
$6.53
열려 있는:
$6.55
하루 거래량:
253.06K
Relative Volume:
0.26
시가총액:
$348.85M
수익:
-
순이익/손실:
$-52.90M
주가수익비율:
-4.5105
EPS:
-1.4433
순현금흐름:
$-48.79M
1주 성능:
-2.11%
1개월 성능:
+32.32%
6개월 성능:
+99.69%
1년 성능:
+48.97%
1일 변동 폭
$6.46
$6.815
1주일 범위
$6.225
$6.815
52주 변동 폭
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
6.51 | 349.92M | 0 | -52.90M | -48.79M | -1.4433 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 재개 | Guggenheim | Buy |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
모두보기
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara Therapeutics (NASDAQ:TARA) Given Buy Rating at HC Wainwright - Defense World
Protara Therapeutics (TARA): HC Wainwright Reiterates Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ETF Watch: Can Protara Therapeutics Inc deliver consistent dividendsJuly 2025 Breakouts & Community Driven Trade Alerts - baoquankhu1.vn
Protara Therapeutics (NASDAQ:TARA) Trading Up 2.3%Should You Buy? - MarketBeat
Protara Therapeutics raises $86.3 million in offering - MSN
Protara Therapeutics reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Protara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Protara hire receives 10,200 options and 5,100 RSUs in inducement grants - stocktitan.net
Day Trade: Is Protara Therapeutics Inc trading at a discountJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
Institutional Investors Have a Lot Riding on Protara Therapeutics, Inc. (NASDAQ:TARA) With 51% Ownership - 富途牛牛
Institution Moves: Whats the profit margin of Protara Therapeutics IncJuly 2025 Chart Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Smart Money: What is the target price for Humacyte Inc Equity Warrant stockRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Aug Sentiment: What is Protara Therapeutics Incs market positionMarket Growth Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
Protara to present bladder cancer treatment data at ASCO symposium By Investing.com - Investing.com Nigeria
Protara to present bladder cancer treatment data at ASCO symposium - Investing.com India
Bladder cancer trial shares new results from 25 patients at ASCO - Stock Titan
How strong is Protara Therapeutics Inc. stock revenue growthRate Hike & Accurate Intraday Trading Signals - bollywoodhelpline.com
Earnings Miss: Is Protara Therapeutics Inc being accumulated by smart moneyQuarterly Performance Summary & Trade Opportunity Analysis - baoquankhu1.vn
Is Immatics NV a strong candidate for buy and hold2025 Major Catalysts & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO Change: What chart patterns are forming on Protara Therapeutics Inc2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Earnings Update: What is the cash position of Protara Therapeutics IncJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected after a year of 5.8% returns - simplywall.st
Weekly Trades: What makes Protara Therapeutics Inc stock attractive todayJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Published on: 2026-01-14 06:06:18 - Bộ Nội Vụ
Protara, Ceribell rise on FDA breakthrough designations - MSN
Protara to report interim results from BCG-unresponsive trial in Q1 - Investing.com Canada
Protara Therapeutics (TARA) Anticipates Key Milestones by 2026 - GuruFocus
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones - GlobeNewswire
Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Piper Sandler - Defense World
Protara Therapeutics (NASDAQ:TARA) Upgraded to Strong-Buy at Piper Sandler - MarketBeat
Revenue per share of Protara Therapeutics, Inc. – DUS:1KPA - TradingView — Track All Markets
Why Protara Therapeutics Inc. stock could see breakout soonPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - Улправда
Sectors Review: Why Protara Therapeutics Inc. stock is recommended by analystsMarket Activity Summary & Fast Gaining Stock Strategy Reports - ulpravda.ru
Is Protara Therapeutics Inc. stock overvalued by current metricsMarket Movers & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Protara Therapeutics completes $75 million stock offering - MSN
Can Protara Therapeutics Inc. stock attract ESG capital inflows2025 Volatility Report & Free Expert Approved Momentum Trade Ideas - Улправда
Why Protara Therapeutics Inc. stock is popular among millennialsJuly 2025 Closing Moves & Weekly Market Pulse Updates - ulpravda.ru
Should I hold or sell Protara Therapeutics Inc. stock in 2025Analyst Downgrade & Risk Adjusted Buy and Sell Alerts - Улправда
Is Protara Therapeutics Inc. stock in correction or buying zoneBull Run & Weekly Watchlist for Hot Stocks - ulpravda.ru
Why Protara Therapeutics Inc. stock is recommended by analysts2025 Price Action Summary & Technical Pattern Alert System - Улправда
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Piper Sandler initiates Protera Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Protara begins patient dosing in phase 3 trial for IV choline therapy - Investing.com Nigeria
Protara Therapeutics (TARA) Begins Phase 3 THRIVE-3 Trial for Ke - GuruFocus
TARA Stock Initiated with 'Overweight' Rating by Piper Sandler | - GuruFocus
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Protara Therapeutics Inc 주식 (TARA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zummo Jacqueline | Chf Scientific Operations Off |
Mar 26 '25 |
Sale |
4.53 |
21,224 |
96,145 |
98,861 |
1.12%
0.87%
자본화:
|
볼륨(24시간):